skip to content
Detailed Quote
5i Report

Review of Knight Therapeutics

AUG 27, 2020 - After a lengthy waiting period for investors, GUD finally closed a large deal in the last quarter of 2019, albeit in a non-traditional way. For patient investors, the potential growth remains while holding a company that provides stability through a large cash position. Rating maintained at B+.

Download Report
Company Profile
Interactive Chart
Key Ratios
Analyst Recommendations
5i Recent Questions
Share Information
News and Media